Preclinical Experts - "Saving, Cleaning Up or Terminating Programs"
Preclinical development does not just refer to going through the motions to get an IND. It is not something that requires "only" research expertise and animal work expertise. It requires people with in-dpeth pathologic and toxicologic understanding who look at all animal data to find those elusive clues that can point towards the future clinical success or failure of a group of compounds, with the ability to stop certain compounds early in favor of others.
XOventure Preclinical Experts provide senior level preclinical research and development expertise, based on decades of experience in toxicologic pathology, regulatory and genetic toxicology. When it is your most important compound, when it is time critical, when it has to be right the first time, you want us on board!
We create the best value for money when used proactively and not just reactively (i.e. troubleshooting). When brought in for troubleshooting we often see that the problems could have been spotted and prevented by the experienced eye much earlier and cheaper.
Our passion is to guide a preclinical program to successfully enter the clinics as fast and as cost effective as possible and handle any preclinical issues in the pre-marketing/marketing phase without loss in patent time or time to market.
Our goal is to put the best opinion available in the world on the table as fast as possible every time. We are equally passionate about applying the pool of expertise to identify and terminate the development of a “loser” compound as early as possible to avoid unnecessary investment.
We want to create transparency in preclinical development that will empower investors to make intelligent informed decisions. This can only be accomplished by a global network of senior independent expert-level preclinical development professionals; it is impossible for one company to hire such a network. It is impossible for such network to exist in one building, one location, and one country or even on one continent. And it is impossible for any single independent consultant to provide the level of support required. If the investors do not get good advice, the system will fail. This we witnessed as a byproduct of the 2008 financial crisis and we do not want to see that again.
We all have heard the numbers, i.e. 9 of 10 leads fail in preclinical and so on. Our network of preclinical professionals cannot pick that 1 candidate that will be successful in human trials. However, we can (and fairly easy) identify those 9 losers, ultimately saving investors and companies millions. Now that’s something to be passionate about!
But even more so, we are passionate about bringing new medicines into the clinics that have the potential to more effectively treat patients and save lives.
Maurice Cary, Senior Partner XOventure & Head of XO Preclinical Expert Group:
|Last Updated on Monday, 22 April 2013 12:33|